Targeting PRMT7 through genetic deletion or inhibition delays chronic myeloid leukemia (CML) development and prevents the self-renewal of leukemic stem cells (LSCs) both in mouse and human CML models. Here, PRMT7 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.